GFPT1 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 5.41739997306223E-09 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
7.70790000000909E-05 |
Normal-vs-Stage2 |
1.240040E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
5.324300E-03 |
Stage1-vs-Stage2 |
6.970200E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
4.911600E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
6.568800E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.12030000001917E-07 |
Normal-vs-AfricanAmerican |
1.795230E-01 |
Normal-vs-Asian |
1.381560E-01 |
Caucasian-vs-AfricanAmerican |
2.858400E-01 |
Caucasian-vs-Asian |
4.517200E-01 |
AfricanAmerican-vs-Asian |
7.624400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
1.22759999998667E-06 |
Normal-vs-Female |
1.001260E-04 |
Male-vs-Female |
4.278400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
4.140700E-03 |
Normal-vs-Extreme_Weight |
3.90559999999818E-05 |
Normal-vs-Obese |
4.998800E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
2.939200E-01 |
Normal_Weight-vs-Obese |
5.419800E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
7.674000E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
2.619000E-01 |
Normal-vs-Age(41-60Yrs) |
1.72811999999967E-05 |
Normal-vs-Age(61-80Yrs) |
1.597440E-04 |
Normal-vs-Age(81-100Yrs) |
9.95589999996938E-07 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.481800E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.687000E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.712810E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.182000E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.499400E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.747400E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
5.191200E-01 |
Normal-vs-Grade 3 |
9.986000E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
3.364600E-01 |
Grade 2-vs-Grade 4 |
5.191200E-01 |
Grade 3-vs-Grade 4 |
9.986000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
2.22780000003198E-06 |
Normal-vs-N1 |
2.264300E-02 |
N0-vs-N1 |
7.884800E-01 |
|
|